Biopharmax India Profile
Key Indicators
- Authorised Capital ₹ 4.50 Cr
as on 16-11-2024
- Paid Up Capital ₹ 0.18 M
as on 16-11-2024
- Company Age 18 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.70 Cr
as on 16-11-2024
- Satisfied Charges ₹ 3.50 Cr
as on 16-11-2024
- Revenue 236.68%
(FY 2023)
- Profit 452.39%
(FY 2023)
- Ebitda 466.47%
(FY 2023)
- Net Worth 106.29%
(FY 2023)
- Total Assets 21.63%
(FY 2023)
About Biopharmax India
The Company is engaged in the Engineering Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.50 Cr and a paid-up capital of Rs 0.18 M.
The company currently has active open charges totaling ₹4.70 Cr. The company has closed loans amounting to ₹3.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sarel Tov, Atul Pabalkar, and Sandhya Deshpande serve as directors at the Company.
- CIN/LLPIN
U45201PN2006FTC138676
- Company No.
138676
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
15 Sep 2006
- Date of AGM
16 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Biopharmax India Private Limited offer?
Biopharmax India Private Limited offers a wide range of products and services, including Cleaning Machine for Food Industry, CIP System, Architectural & Civil Engineering, Architectural Services, Scientific Instruments, Laboratory Instruments, Machine Parts, Copyright & Trademark, Trademarks Services, Industrial Equipment Installation.
Who are the key members and board of directors at Biopharmax India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sarel Tov  | Director | 30-Jun-2008 | Current |
Sandhya Deshpande  | Director | 27-Jan-2020 | Current |
| Atul Pabalkar | Whole-Time Director | 02-Feb-2022 | Current |
Financial Performance of Biopharmax India.
Biopharmax India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 236.68% increase. The company also saw a substantial improvement in profitability, with a 452.39% increase in profit. The company's net worth Soared by an impressive increase of 106.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biopharmax India?
In 2023, Biopharmax India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Oct 2016 | ₹4.70 Cr | Open |
Icici Bank Limited Creation Date: 27 Feb 2013 | ₹3.50 Cr | Satisfied |
How Many Employees Work at Biopharmax India?
Biopharmax India has a workforce of 65 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biopharmax India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biopharmax India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
